Wells Fargo Downgrades Integra Lifesciences to Equal-Weight, Lowers Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Vik Chopra downgraded Integra Lifesciences (IART) from Overweight to Equal-Weight and reduced the price target from $45 to $25.

May 07, 2024 | 12:43 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Wells Fargo downgraded Integra Lifesciences to Equal-Weight and lowered its price target to $25.
The downgrade from Overweight to Equal-Weight by a major financial institution like Wells Fargo, accompanied by a significant reduction in the price target, is likely to negatively impact investor sentiment towards IART in the short term. This could lead to a decrease in stock price as market participants adjust their expectations based on the new analyst rating and price target.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100